Clinical Characteristics and Prognosis Analysis of Angioimmunoblastic T-Cell Lymphoma.
10.19746/j.cnki.issn.1009-2137.2025.01.015
- Author:
Hong-Bo WANG
1
;
Xiu-Juan WANG
1
;
Xin-Hong GUO
1
Author Information
1. Hematologic Disease Center, The First Affiliated Hospital of Xinjiang Medical University (Institute of Hematology of Xinjiang Uygur Autonomous Region), Urumqi 830054, Xinjiang Uygur Autonomous Region, China.
- Publication Type:Journal Article
- Keywords:
angioimmunoblastic T-cell lymphoma;
clinical characteristics;
prognosis;
multiple serous effusion;
interleukin-6
- MeSH:
Humans;
Prognosis;
Male;
Aged;
Retrospective Studies;
Middle Aged;
Female;
Adult;
Aged, 80 and over;
Lymphoma, T-Cell/diagnosis*;
Immunoblastic Lymphadenopathy/diagnosis*;
Young Adult;
Survival Rate;
Kaplan-Meier Estimate
- From:
Journal of Experimental Hematology
2025;33(1):108-113
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To investigate the clinical characteristics and prognostic factors of patients with angioimmunoblastic T-cell lymphoma (AITL).
METHODS:A retrospective analysis was conducted on the clinical data of 42 AITL patients who were diagnosed and monitored in the Hematologic Disease Center of the First Affiliated Hospital of Xinjiang Medical University from 2011 to 2021. Kaplan-Meier method was used to calculate overall survival (OS) rate and progression-free survival (PFS) rate, while log-rank method was utilized for comparison.
RESULTS:The majority of 42 patients were elderly, with a median age at diagnosis of 66(22-80) years old, and 25 cases were males. There were 38 patients in Ann Arbor stage III-IV, 23 patients with B symptoms, and 34 patients with intermediate-high to high risk of International Prognostic Index (IPI) score. The most common clinical manifestation was painless lymph node swelling (31 cases), which could be accompanied by multiple serous effusion (24 cases), fever (17 cases), rash (11 cases), and anemia (15 cases). There were 18 patients with positive Epstein-Barr virus (EBV), 28 patients with Ki-67 ≥40%, and 6 patients accompanied by EBV viremia. The median survival time of the 42 patients was 12(1-121) months, 3-year OS rate was 37.6%, and 3-year PFS rate was 26.1%. Univariate analysis indicated that patients with elevated interleukin (IL)-6 and multiple serous effusion exhibited lower survival rate.
CONCLUSION:AITL is characterized by diverse clinical manifestations, high aggressiveness and poor prognosis. Conventional chemotherapy is not effective. Elevated IL-6 and multiple serous effusion are poor prognostic factors for AITL patients.
